From: KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
Target | Tested drug | Phase trial | Population | Primary Outcomes |
---|---|---|---|---|
ALK | ceritinib | Phase I NCT02227940 | Dose escalation (ALK negative) and expansion cohort (ALK positive) in advanced solid tumors in combination with standard chemotherapy Expansion cohort 2E: advanced pancreatic cancer ALK positive in combination with gemcitabine and nab-paclitaxel | MTD, RP2D |
BRAF | binimetinib + encorafenib | Phase II NCT04390243 | Pancreatic cancer BRAF mutated (V600E) after progression disease to at least one line of chemotherapy | ORR |
MEK | cobimetinib or olaparib trametinib + hydroxychloroquine | Early Phase 1 NCT04005690 Phase I NCT03825289 | Diagnosis of pancreatic cancer (resectable, borderline resectable, or advanced) are eligible Participants may be treatment naive or have received prior therapy Arm I: cobimetinib Arm II: Olaparib Pretreated Advanced Pancreatic Cancer | Assess the feasibility of collecting tumor tissue for biomarker evaluation prior to and after window therapy with either cobimetinib or olaparib DLT, RP2D |
RET | selpercatinib sunitinib | EAP NCT03906331 Phase IV NCT02691793 | Solid tumors RET activated RET fusion positive, FGFR2 fusion/FGFR mutation refractory solid tumor | - PFS |
NTRK/ROS1 | entrectinib | Phase II NCT02568267 (STARTRK2) | Solid tumors with NTRK1/2/3, ROS1, ALK gene rearrangments | ORR |
NTRK | VDM-928 | Phase I NCT03556228 | Expansion phase: Solid tumors with NTRK1 gene fusions or amplification | AEs |
NTRK/ROS1 | DS-6051b | Phase I NCT02279433 | advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement | DLT |
NRG1 | zenocutuzumab (MCLA-128) | Phase I/II NCT02912949 | Dose escalation (NRG1 negative) and dose expansion (NRG1 positive) in advanced solid tumors Dose expansion Group G: pancreatic cancer with NRG1 fusion | AEs / SAEs ORR DOR Biomarkers analysis |
HER2 | A116 | Phase I/II NCT03602079 | Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | Phase I: MTD Phase II: ORR |
ACE1702 | Phase I NCT0431975 | Advanced or Metastatic HER2-expressing Solid Tumors | Safety, DLT, MTD, RP2D | |
T-DXd | Phase2 NCT04482309 | cohort six: patient with no satisfactory alternative treatment option affected by advanced pancreatic cancer with HER2 amplification | ORR | |
afatinib + capecitabine | Phase I/IB NCT02451553 | Phase I: pretreated solid tumor Phase IB: pretreated advanced pancreatic and biliary tract cancer | DLT, MTD, RP2D | |
ERK | LY3214996 +/− hydroxychloroquine | Phase II NCT04386057 | Advanced pancreatic cancer | DCR |
ulixertinib/Palbociclib | Phase I NCT03454035 | Dose escalation cohorts: histologically confirmed advanced refractory solid tumor | MTD | |
Expansion: metastatic pancreatic cancer patients | OS | |||
MSI | dostarlimab | Phase I NCT02715284 | Part 2B: Cohort F non-endometrial dMMR/MSI-H or POLE-Mutated solid tumors, that have progressed following up to 2 prior lines of systemic for advanced disease | AE |
FGFR | pemigatinib | Phase II NCT03822117 | Cohort A Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR 1–3 fusion | ORR |
infigratinib | Phase II NCT04233567 | Cohort 1–2: solid tumor harboring FGFR1–3 fusion/translocation who have progressed on or are intolerant to standard of care | ORR | |
erdafitinib | Phase II NCT04083976 | Pretreated advanced solid tumor malignancy FGFR mutation or gene fusion | ORR | |
debio 1347 | Phase II NCT03834220 | Pretreated Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3 | ORR |